{"id":24687,"date":"2025-06-10T09:47:10","date_gmt":"2025-06-10T04:17:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24687"},"modified":"2025-06-11T09:48:24","modified_gmt":"2025-06-11T04:18:24","slug":"bispecific-antibodies-for-multiple-myeloma-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment","title":{"rendered":"A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f9a7e2482e6\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f9a7e2482e6\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\/#What_is_new_in_the_field_of_bispecific_antibodies_for_multiple_myeloma_treatment_in_2023\" >What is new in the field of bispecific antibodies for multiple myeloma treatment in 2023?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\/#What_is_the_main_target_of_bispecific_and_CAR-T_cell_therapies\" >What is the main target of bispecific and CAR-T cell therapies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\/#Who_Will_Win_the_Battle_of_Bispecifics_in_RelapsedRefractory_Multiple_Myeloma\" >Who Will Win the Battle of Bispecifics in Relapsed\/Refractory Multiple Myeloma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\/#Are_bispecific_antibodies_better_than_CAR-Ts\" >Are bispecific antibodies better than CAR-Ts?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\/#Summary\" >Summary<\/a><\/li><\/ul><\/nav><\/div>\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed\/refractory multiple myeloma treatment segment.<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<p>Currently, the FDA has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are approved for oncology indications, <span style=\"box-sizing: border-box; margin: 0px; padding: 0px;\">primarily hematological malignancies, including multiple myeloma and\u00a0<a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\" class=\"ek-link\"><strong>diffuse large B-cell lymphoma\u00a0<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\" target=\"_blank\" rel=\"noopener\"><strong>(<\/strong><\/a><\/a><\/span><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\" class=\"ek-link\">DLBCL)<\/a><\/strong>. Only two bispecific antibodies, <a href=\"https:\/\/www.delveinsight.com\/blog\/hemlibra-for-hemophilia-a-treatment\">HEMLIBRA<\/a> and VABYSMO, are authorized for non-oncology indications such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a2030-market\"><strong>hemophilia A<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/neovascular-age-related-macular-degeneration-market\"><strong>neovascular (wet) age-related macular degeneration<\/strong><\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-macular-edema-dme-market\"><strong>diabetic macular edema<\/strong><\/a>, respectively. The FDA authorized three bispecific antibodies (<a href=\"https:\/\/www.delveinsight.com\/report-store\/vabysmo-market-drug-insight-and-market-forecast\"><strong>VABYSMO<\/strong><\/a>, TECVAYLI, and LUNSUMIO) and one bispecific molecule (KIMMTRAK) in 2022.\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"175\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-1024x175.png\" alt=\"\" class=\"wp-image-28934\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-1024x175.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-300x51.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-150x26.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-768x131.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-1536x263.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-2048x351.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30114929\/Bispecific-Antibodies-In-Therapy-Area-1568x268.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The <strong>multiple myeloma treatment market<\/strong> is rapidly evolving, and current and emerging key players face significant risk due to this high degree of innovation. <a href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugates-adcs-in-oncology\">Antibody-drug conjugate (ADC)<\/a>, CAR-T cell treatments, and bispecific antibodies are just a few of the novel modes of action that have recently entered the market for later lines of therapy. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecifics-trispecifics-competitive-landscape-and-market-forecast\"><strong>bispecific antibodies market<\/strong><\/a>, in particular, is anticipated to evolve in the coming years, with multiple companies entering the <a href=\"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-treatment\">multiple myeloma treatment space <\/a>with their products. Johnson &amp; Johnson (J&amp;J) dominates this field by adding two bispecific antibodies approved in the bispecific antibodies market. TECVAYLI (teclistamab) became the first bispecific antibody to receive regulatory approval for treating relapsed\/refractory multiple myeloma (RRMM) in 2022 in the United States and Europe. Later in 2023, TALVEY (talquetamab) and ELREXFIO (elranatamab) were approved for RRMM.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-new-in-the-field-of-bispecific-antibodies-for-multiple-myeloma-treatment-in-2023\"><span class=\"ez-toc-section\" id=\"What_is_new_in_the_field_of_bispecific_antibodies_for_multiple_myeloma_treatment_in_2023\"><\/span><strong>What is new in the field of bispecific antibodies for multiple myeloma treatment in 2023?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Several multispecific antibodies under development are also making progress. Bispecific antibodies have seen significant progress for hematological oncology indications in the last few years, especially in 2022 and 2023. In August 2023, the FDA approved four bispecific antibodies for indications like DLBCL and Multiple Myeloma. Some recent developments in the field of bispecific antibodies for multiple myeloma are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>November 2024,<\/strong> <strong>Nanjing Leads Biolabs Co., Ltd<\/strong>. announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting GPRC5D and CD3 for multiple myeloma, has received Orphan Drug Designation (ODD) from the FDA.<\/li>\n\n\n\n<li>At the <strong>EHA Congress<\/strong> in Madrid held in <strong>June 2024,<\/strong> Regeneron showcased linvoseltamab&#8217;s promising Phase I\/II results for multiple myeloma. This BCMA and CD3-targeting bispecific antibody, developed with VelociGene and VelocImmune, demonstrated potential in treating the disease.<\/li>\n\n\n\n<li>On <strong>10 August 2023, J&amp;J<\/strong> received FDA approval for its second bispecific antibody <strong>TALVEY (talquetamab)<\/strong>, for treating RRMM, who have received at least four prior lines of therapy.<\/li>\n\n\n\n<li>In <strong>August 2023<\/strong>, the US FDA approved a third bispecific antibody<strong> ELREXFIO (elranatamab)<\/strong>, for treating RRMM who have received at least four prior lines of therapy.<\/li>\n\n\n\n<li>In<strong> August 2023, J&amp;J<\/strong> received approval from the European Commission (EC) for <strong>TECVAYLI<\/strong>, providing the option for a reduced dosing frequency of 1.5mg\/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months.<\/li>\n\n\n\n<li>Based on the Phase II results of <strong>linvoseltamab, Regeneron Pharmaceuticals<\/strong> plans to submit a Biologics License Application (BLA) to the FDA in the second half of 2023 in RRMM.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-1024x194.webp\" alt=\"Multiple Myeloma infographic\" class=\"wp-image-28937\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115430\/Multiple-Myeloma-infographic.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-the-main-target-of-bispecific-and-car-t-cell-therapies\"><span class=\"ez-toc-section\" id=\"What_is_the_main_target_of_bispecific_and_CAR-T_cell_therapies\"><\/span><strong>What is the main target of bispecific and CAR-T cell therapies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\">pipeline analysis of multiple myeloma<\/a>, B-cell maturation antigen (BCMA) is the primary target for bispecific and CAR-T cell therapies. Most approved and investigational medicines of the above-mentioned technologies target a protein known as BCMA. With several FDA-approved therapies, BCMA has emerged as a hot target in multiple myeloma. BCMA is frequently expressed on the surface of the malignant plasma cells that characterize this cancer type, which is key to its potential in multiple myeloma therapy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"292\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-1024x292.png\" alt=\"Emerging Bispecific Antibodies Under Investigation for Multiple Myeloma\" class=\"wp-image-28938\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-1024x292.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-300x86.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-150x43.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-768x219.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-1536x438.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-2048x584.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115545\/Emerging-Bispecific-Antibodies-Under-Investigation-for-Multiple-Myeloma-1568x447.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-who-will-win-the-battle-of-bispecifics-in-relapsed-refractory-multiple-myeloma\"><span class=\"ez-toc-section\" id=\"Who_Will_Win_the_Battle_of_Bispecifics_in_RelapsedRefractory_Multiple_Myeloma\"><\/span><strong><strong>Who Will Win the Battle of Bispecifics in Relapsed\/Refractory Multiple Myeloma?<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Johnson &amp; Johnson\u2019s (J&amp;J) TECVAYLI (BCMA \u00d7 CD3) is the first bispecific antibody to be approved for <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma treatment<\/a>. It targets BCMA, a protein that is highly expressed in myeloma cells, and CD3, a protein that is essential for T-cell activation. TECVAYLI is J&amp;J\u2019s fourth approved therapy for multiple myeloma treatment, adding to the company\u2019s industry-leading oncology portfolio. TECVAYLI is a ready-to-use therapy that does not require customization for each patient. In a Phase II trial involving 110 patients who had received a median of five prior lines of therapy, TECVAYLI achieved an overall response rate (ORR) of 61.8%, with 28.2% of patients reaching a complete response (CR) or better.&nbsp;<\/p>\n\n\n\n<p>he MajesTEC-1 study revealed that, with a median follow-up of 30.4 months, patients treated with TECVAYLI at the recommended Phase II dose (RP2D) showed an overall response rate (ORR) of 63%. Notably, 46% of these patients achieved a complete response (CR) or better, with responses continuing to improve.<\/p>\n\n\n\n<p><em>\u201cOver the past two years, TECVAYLI has treated over 10,000 patients with relapsed or refractory multiple myeloma,\u201d said Rachel Kobos, M.D., VP of Oncology R&amp;D at Johnson &amp; Johnson. \u201cWith strong clinical and real-world data, we&#8217;re committed to meeting unmet needs in myeloma and advancing new treatments, including for frontline use.\u201d<\/em><\/p>\n\n\n\n<p>In February 2024, the FDA approved a supplemental Biologics License Application (sBLA) for TECVAYLI, allowing a reduced dose of 1.5 mg\/kg every two weeks for relapsed\/refractory multiple myeloma patients in sustained complete response (CR) for at least six months.<\/p>\n\n\n\n<p>Pfizer\u2019s ELREXFIO is currently a main competitor of J&amp;J\u2019s TECVAYLI. ELREXFIO (elranatamab) is the second BCMA \u00d7 CD3 <a href=\"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-treatment\">bispecific antibody approved for RRMM<\/a> in 2023. ELREXFIO is similar to TECVAYLI in its mechanism of action, but it has a different structure and dosing regimen. In the Phase I\/II trial involving <strong>149 patients <\/strong>who had received a median of six prior lines of therapy, ELREXFIO achieved an ORR of <strong>61%, with 19% <\/strong>of patients reaching a CR or better. ELREXFIO faces direct competition from TECVAYLI as well as from other bispecific antibodies in development that target BCMA and CD3, such as <strong>Linvoseltamab <\/strong>and <strong>REGN5459 <\/strong>by <strong>Regeneron Pharmaceuticals, <\/strong>and <strong>ABBV-383 (TNB383B) by AbbVie<\/strong>.<\/p>\n\n\n\n<p>In June 2024, the MagnetisMM-3 trial data showed that after over two years of follow-up, patients receiving ELREXFIO achieved an overall response rate (ORR) of <strong>61.0%,<\/strong> with <strong>37.4%<\/strong> reaching a complete response (CR). Responses continued to improve over time, and the median duration of response (DOR) was not yet reached. At two years, the estimated DOR rate was <strong>66.9%<\/strong> for all responders and <strong>87.9%<\/strong> for those with a CR or better. Median progression-free survival (PFS) was <strong>17.2 months<\/strong>, with a PFS rate of <strong>90.6%<\/strong> at two years for patients with a CR or better response.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"394\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-1024x394.png\" alt=\"Roadmap for Bispecific Antibody Approval in the United States\" class=\"wp-image-28939\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-1024x394.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-300x115.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-768x295.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-1536x591.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-2048x788.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115707\/Roadmap-for-Bispecific-Antibody-Approval-in-the-United-States-1568x603.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>So far, findings from BCMA \u00d7 CD3-directed bispecific antibodies are comparable, although ELREXFIO appears to have a convenience advantage. The ability of ELREXFIO to be dosed every other week after<strong> 24 weeks <\/strong>of weekly therapy has given it an advantage over TECVAYLI. J&amp;J\u2019s TECVAYLI is currently being administered weekly throughout the maintenance period. However, J&amp;J has filed additional data to make TECVAYLI a biweekly therapy as well.<\/p>\n\n\n\n<p>TALVEY (GPRC5D \u00d7 CD3) is another bispecific antibody from J&amp;J\u2019s portfolio that was approved for RRMM. It targets G protein-coupled receptor family C group 5 member D (GPRC5D), a new protein that is also highly expressed in myeloma cells, and CD3. TALVEY became J&amp;J\u2019s fifth novel medicine and second bispecific antibody authorized for treating multiple myeloma. In <strong>Phase I\/II trial involving 184 patients <\/strong>who had received a median of six prior lines of therapy, <strong>TALVEY <\/strong>achieved an <strong>ORR of 73%,<\/strong> with <strong>25%<\/strong> of patients reaching a CR or better. J&amp;J is also testing a combination of TALVEY and TECVAYLI in <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-multiple-myeloma-market\">RRMM patients<\/a>. The combination showed early signs of efficacy and safety in a Phase I trial. The launch price of<strong> BCMA \u00d7 CD3-<\/strong>directed bispecific antibodies are comparable. However, TALVEY\u2019s per-month charge of <strong>USD 45,000<\/strong> is greater than TECVAYLI\u2019s price of<strong> USD 39,500.&nbsp;<\/strong><\/p>\n\n\n\n<p>In a recent MonumenTAL-1 study, Talvey showed an ORR of over 71% in RRMM patients, many of whom were refractory to five previous treatments. While response duration is still being assessed, Talvey is noted for enhancing patients&#8217; quality of life.<\/p>\n\n\n\n<p>In September 2024, the RedirecTT-1 Phase Ib study (NCT04586426) reported that TALVEY combined with TECVAYLI achieved durable responses in patients with triple-class-exposed relapsed\/refractory multiple myeloma. Findings were presented at the <strong>21st Annual International Myeloma Society Meeting<\/strong>.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-a4a0532a-7fff-80bf-4ea5-e44242944018\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"101\" \/><col width=\"108\" \/><col width=\"119\" \/><col width=\"134\" \/><col width=\"187\" \/><\/colgroup>\n<thead>\n<tr style=\"height: 0pt;\">\n<th style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" colspan=\"5\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">WAC List Price for Approved Bispecific Antibodies for the Treatment of Multiple Myeloma in the United States<\/span><\/p>\n<\/th>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug Name<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company Name<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Approval Date<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">List Price<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(in USD)<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Entire Treatment Regimen Cost<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(in USD)<\/span><\/p>\n<\/th>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">TECVAYLI<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">J&amp;J<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">October 2022<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">39,500 per month<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">355,500&ndash;395,000<\/span><\/p>\n<\/th>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">TALVEY<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">J&amp;J<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">August 2023<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">45,000 per month<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">270,000&ndash;360,000<\/span><\/p>\n<\/th>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ELREXFIO<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Pfizer<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">August 2023<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">41,500 per month<\/span><\/p>\n<\/th>\n<th style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" scope=\"col\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">330,000<\/span><\/p>\n<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Another bispecific antibody from Regeneron Pharmaceuticals is set to join the multiple myeloma foray. Regeneron\u2019 Linvoseltamab could become the third bispecific antibody to receive FDA approval that targets BCMA and CD3. In a Phase II trial involving 121 patients who had received a median of five prior lines of therapy, linvoseltamab achieved an <strong>ORR of 64% <\/strong>in the <strong>200 mg dose <\/strong>group and <strong>50%<\/strong> in the <strong>50 mg dose group.<\/strong> Linvoseltamab is being studied in a broad clinical program as both monotherapy and in combination across various treatment lines in multiple myeloma, including earlier-stage disease and plasma cell precursor disorders. Ongoing trials include the <strong>Phase Ib LINKER-MM2 study<\/strong> evaluating combination regimens in relapsed\/refractory MM and the <strong>Phase III LINKER-MM3<\/strong> confirmatory trial assessing linvoseltamab as monotherapy in the same setting.<\/p>\n\n\n\n<p>In February 2025, Regeneron announced that the FDA accepted the resubmitted <strong>Biologics License Application (BLA)<\/strong> for <strong>linvoseltamab <\/strong>to treat adults with <strong>relapsed\/refractory multiple myeloma (MM)<\/strong> who have undergone at least four prior therapies or three prior therapies and are refractory to the last. The FDA\u2019s target action date is <strong>July 10, 2025<\/strong>.<\/p>\n\n\n\n<p>The resubmission follows the resolution of third-party manufacturing issues, the only approvability concern in the previous submission. Supported by data from the pivotal LINKER-MM1 trial, linvoseltamab is also under review by the European Medicines Agency (EMA) for the same indication.<\/p>\n\n\n\n<p>REGN5459 is another bispecific antibody by Regeneron Pharmaceuticals that targets BCMA and CD3. It is still in Phase I\/II development and has shown impressive results in efficacy and safety. In a study involving 43 patients who had received a median of seven prior lines of therapy, <strong>REGN5459 <\/strong>achieved an <strong>ORR <\/strong>of <strong>65.1%<\/strong>, with <strong>61.9%<\/strong> of patients reaching a CR or better among the 21 patients treated at the higher doses (480 mg and 900 mg). However, the primary completion date of the trial is by November 2025, and Regeneron Pharmaceuticals seems to focus more on linvoseltamab.&nbsp;<\/p>\n\n\n\n<p>ABBV-383 (TNB383B) is another bispecific antibody that targets BCMA and CD3. AbbVie is developing it in collaboration with Teneobio. In June 2024, AbbVie announced the first patient dosing in the Phase III CERVINO study of ABBV-383, a bispecific BCMA-CD3 T-cell engager with high BCMA avidity and low-affinity CD3 binding. The trial evaluates ABBV-383 against standard therapies in relapsed\/refractory multiple myeloma patients who have received at least two prior treatments. Dr. Peter Voorhees, clinical professor of medicine and director of plasma cell disorders at Atrium Health Levine Cancer Institute, stated, <em>&#8220;The CERVINO Phase III trial is designed to evaluate the efficacy of ABBV-383 with monthly dosing, and we look forward to seeing the data as it emerges.&#8221;<\/em>&nbsp;&nbsp;<\/p>\n\n\n\n<p>Cevostamab is a bispecific antibody that targets FcRH5, a protein related to BCMA but with lower expression on normal B cells and CD3. Developed by Roche, cevostamab is still in Phase I\/II development and is being evaluated for its potential in treating relapsed\/refractory multiple myeloma (RRMM).<\/p>\n\n\n\n<p>The CAMMA-2 Phase I\/II study (NCT05535244) is assessing the efficacy and safety of cevostamab in patients with RRMM who are triple-class refractory and have previously received a BCMA-targeted therapy. Initial results from Cohort A1 of the trial were presented at EHA 2024.<\/p>\n\n\n\n<p>At the data cut-off, with a median follow-up of 11 months, 6 out of 14 responders remained in response. The overall response rate (ORR) was 67%, with the prior ADC group achieving an ORR of 60% and a very good partial response or better (\u2265VGPR) in 20% of patients. In the prior CAR T-cell group, the ORR reached 73%, with 55% achieving \u2265VGPR. These promising results highlight cevostamab&#8217;s potential as a novel therapy for patients previously treated with BCMA-targeted approaches.&nbsp;<\/p>\n\n\n\n<p>Cevostamab has the lowest ORR among all the bispecific antibodies, and Roche has not announced any anticipated BLA filing plans for this <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma therapy<\/a>.&nbsp;<\/p>\n\n\n\n<p>Dr. Richter presented data from the ongoing CAMMA-2 trial at <a href=\"https:\/\/www.delveinsight.com\/eha-conference\/eha-2024\">EHA 2024<\/a>, focusing on relapsed and refractory multiple myeloma patients who have progressed despite BCMA-based therapies. These patients may have previously received treatments like teclistamab (Tecvayli), belantamab-mafodotin (Blenrep), or CAR T-cell therapies such as ide-cel (Abecma) and cilta-cel (Carvykti).<\/p>\n\n\n\n<p>The trial is still recruiting, but if successful, cevostamab could be approved as a monotherapy for BCMA-exposed myeloma patients, offering a new treatment option.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-a4a0532a-7fff-80bf-4ea5-e44242944018\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<table style=\"border: none;\"><colgroup><col width=\"92\" \/><col width=\"106\" \/><col width=\"61\" \/><col width=\"94\" \/><col width=\"103\" \/><col width=\"118\" \/><col width=\"75\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" colspan=\"7\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Efficacy comparison of Bispecific antibodies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Bispecific Antibody<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Developer<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Target<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Trial Acronym<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Current Developmental Status<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">ORR (%)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">CR (%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 26.5pt;\">\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">TECVAYLI<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">J&amp;J<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">BCMA &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">MajesTEC-1<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Approved<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">1<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">61.8%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">28.2%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">TALVEY<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">J&amp;J<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">GPRC5D &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">MonumenTAL-1<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Approved<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">1<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">73%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">25%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">ELREXFIO<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Pfizer<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">BCMA &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">MagnetisMM-3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Approved<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">1<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">61%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">19%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Linvoseltamab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Regeneron Pharmaceuticals<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">BCMA &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">LINKER-MM1<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Expected approval by 2024<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">64% (200 mg dose)&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">50% (50 mg dose)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Not reported<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Cevostamab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Roche<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">FcRH5 &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">CAMMA 2<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Phase I\/II&nbsp;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">46.7% (overall)&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">54.5% (160 mg dose) 36.7% (90 mg dose)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">13.3%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">REGN5459<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Regeneron Pharmaceuticals<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">BCMA &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Phase I\/II&nbsp;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">65.1% (overall)&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">90.5% (higher doses, i.e., 480 mg and 900 mg)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">61.9% (higher doses)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">ABBV-383 (TNB383B)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">AbbVie\/<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Teneobio<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">BCMA &times; CD3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Phase I\/II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">79%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #ffffff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">34%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f2f2f2; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #dbbccc 0.5pt;\" colspan=\"7\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; vertical-align: baseline; white-space-collapse: preserve;\">Note: These drugs are actively being researched in combination and for treatment in different settings in Multiple Myeloma patients.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<span id=\"docs-internal-guid-86a26c50-7fff-373f-7987-68dac9dc62ac\"><\/span><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Companies are trying to get to early lines of treatment settings now that the FDA has approved bispecific antibodies in later lines. However, it is too early to predict patient outcomes and performance. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecific-antibody-competitive-landscape\">bispecific antibody market<\/a> is projected to grow overcrowded as a result of many approvals and intensive pipeline activity. The competition between drugs with similar targets will be fierce. For example, there are many BCMA-targeting drugs on the market, two <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\"><strong>CAR-T cell therapies<\/strong><\/a>, and two bispecific antibodies, and some are expected to receive regulatory approval by next year in a later line. Moving into the early lines of setup would be the ideal plan for key pharma players. J&amp;J and Pfizer are working extensively to broaden the label of their respective bispecific antibodies since both companies are conducting clinical trials in an array of settings with and without combination.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"494\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-1024x494.png\" alt=\"Multiple Myeloma Market Size by Bispecific Antibodies in 4L\" class=\"wp-image-28940\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-1024x494.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-300x145.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-150x72.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-768x371.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-1536x742.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-2048x989.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30115821\/Multiple-Myeloma-Market-Size-by-Bispecific-Antibodies-in-4L-1568x757.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-are-bispecific-antibodies-better-than-car-ts\"><span class=\"ez-toc-section\" id=\"Are_bispecific_antibodies_better_than_CAR-Ts\"><\/span><strong>Are bispecific antibodies better than CAR-Ts?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Both CAR T-cell therapy and bispecific treatment are gaining popularity. Both drugs have induced profound and long-lasting responses in R\/R patients, which has never been seen previously. The question is, which is better for patients, CAR T-cell therapy or bispecific therapy? Both therapies have advantages and disadvantages. CAR T-cell therapy is a \u201cone-and-done\u201d therapy, whereas bispecific therapies are not. Bispecific antibodies require ongoing treatment. CAR-T therapies have shown remarkable efficacy in multiple myeloma, but they also have some drawbacks, such as the risk of <a href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-market\">cytokine release syndrome (CRS)<\/a>, a potentially life-threatening inflammatory reaction. CRS can also occur with bispecific antibodies but is usually less severe than CAR-T therapies.<\/p>\n\n\n\n<p>Regarding safety, none of the bispecific antibodies exhibit unusual neurotoxicity, which is a major advantage for bispecific antibodies over <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\"><strong>CAR-T cell therapies for multiple myeloma<\/strong><\/a>. In terms of safety, bispecific antibodies are a clear winner, and owing to the high-grade CRS, high-grade neurotoxicity, and Grade 3 or higher of BCMA-directed CAR T-cell therapies, bispecific antibodies are likely to be preferred by oncology experts. Another challenge for CAR-T therapies is the cost, convenience, and time required to produce them, as each patient needs a personalized product. Bispecific antibodies, on the other hand, are ready-made (off-the-shelf) and can be administered more easily, which is a major advantage. Another key issue with CAR-T is market access. The cost and access aspects are where bispecific antibodies can truly make a difference. Bispecific antibodies may also be more suitable for older patients or those with other health problems who cannot receive CAR-T therapies. Like CAR-T cell therapies, bispecific antibodies are increasingly making their way to the front lines.<\/p>\n\n\n\n<p>It may be possible to combine CAR-T therapies and bispecific antibodies to target different proteins in myeloma cells and achieve a cure for this disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-summary\"><span class=\"ez-toc-section\" id=\"Summary\"><\/span><strong>Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To summarize, bispecific antibodies are emerging as a new class of therapies, and J&amp;J is leading the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\"><strong>multiple myeloma treatment market<\/strong><\/a> with two approved bispecific antibodies, TECVAYLI and TALVEY, which target BCMA and CD3, and GPRC5D and CD3, respectively. Pfizer has also entered the multiple myeloma treatment market with ELREXFIO, another bispecific antibody that targets BCMA and CD3. J&amp;J has better experience and a competitive advantage in the multiple myeloma treatment space. DARZALEX from J&amp;J is the top CD38 antibody with regulatory approval across all therapy lines. To cut a long story short, following the success of monoclonal antibodies and CAR-T, many researchers believe bispecific antibodies can change the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">treatment landscape of multiple myeloma<\/a> and will represent a new dimension of precision treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1024x194.png\" alt=\"Multiple Myeloma Market Outlook and Insights\" class=\"wp-image-28816\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed\/refractory multiple myeloma treatment segment. Currently, the FDA has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are approved for oncology indications, primarily hematological malignancies, including multiple myeloma and\u00a0diffuse large B-cell lymphoma\u00a0(DLBCL). Only [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":24689,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19285,19286,410,16669,16671,19906,16672,20354],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-24687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bispecific-antibody","tag-bispecific-antibody-clinical-trials","tag-multiple-myeloma","tag-multiple-myeloma-market","tag-multiple-myeloma-pipeline","tag-multiple-myeloma-treatment","tag-multiple-myeloma-treatment-market","tag-relapsed-refractory-multiple-myeloma","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bispecific Antibodies: Next Chapter in Multiple Myeloma Treatment<\/title>\n<meta name=\"description\" content=\"Bispecific antibodies emerging as new class of therapies and J&amp;J is leading multiple myeloma space with two approved bispecific antibodies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bispecific Antibodies: Next Chapter in Multiple Myeloma Treatment\" \/>\n<meta property=\"og:description\" content=\"Bispecific antibodies emerging as new class of therapies and J&amp;J is leading multiple myeloma space with two approved bispecific antibodies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T04:17:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-11T04:18:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/28161839\/bispecific-antibodies-for-multiple-myeloma-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bispecific Antibodies: Next Chapter in Multiple Myeloma Treatment","description":"Bispecific antibodies emerging as new class of therapies and J&J is leading multiple myeloma space with two approved bispecific antibodies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment","og_locale":"en_US","og_type":"article","og_title":"Bispecific Antibodies: Next Chapter in Multiple Myeloma Treatment","og_description":"Bispecific antibodies emerging as new class of therapies and J&J is leading multiple myeloma space with two approved bispecific antibodies","og_url":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-10T04:17:10+00:00","article_modified_time":"2025-06-11T04:18:24+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/28161839\/bispecific-antibodies-for-multiple-myeloma-treatment.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment","url":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment","name":"Bispecific Antibodies: Next Chapter in Multiple Myeloma Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/28161839\/bispecific-antibodies-for-multiple-myeloma-treatment.webp","datePublished":"2025-06-10T04:17:10+00:00","dateModified":"2025-06-11T04:18:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Bispecific antibodies emerging as new class of therapies and J&J is leading multiple myeloma space with two approved bispecific antibodies","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/28161839\/bispecific-antibodies-for-multiple-myeloma-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/28161839\/bispecific-antibodies-for-multiple-myeloma-treatment.webp","width":1200,"height":800,"caption":"bispecific-antibodies-for-multiple-myeloma-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/28161839\/bispecific-antibodies-for-multiple-myeloma-treatment-300x200.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">bispecific antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">bispecific antibody clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Relapsed\/Refractory Multiple Myeloma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">bispecific antibody<\/span>","<span class=\"advgb-post-tax-term\">bispecific antibody clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Relapsed\/Refractory Multiple Myeloma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Jun 10, 2025","modified":"Updated on Jun 11, 2025"},"absolute_dates_time":{"created":"Posted on Jun 10, 2025 9:47 am","modified":"Updated on Jun 11, 2025 9:48 am"},"featured_img_caption":"bispecific-antibodies-for-multiple-myeloma-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24687"}],"version-history":[{"count":10,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24687\/revisions"}],"predecessor-version":[{"id":32415,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24687\/revisions\/32415"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/24689"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24687"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24687"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}